Key result
Baseline carboxymethyl-lysine levels were not significantly associated with the risk of incident peripheral artery disease (HR per SD increment 1.03; 95% CI 0.87-1.23).
Why the study?
Higher carboxymethyl-lysine levels have been associated with increased risk of coronary heart disease, stroke, and cardiovascular mortality, but their association with incident peripheral artery disease was unclear.
Are high baseline carboxymethyl-lysine levels associated with an increased risk of incident peripheral artery disease in older adults?
Cohort (n=3,267)
Are high baseline carboxymethyl-lysine levels associated with an increased risk of incident peripheral artery disease in older adults?
Baseline serum carboxymethyl-lysine levels are not significantly associated with the risk of incident peripheral artery disease in older adults.
Answers are grounded in this paper and cite their sources.
CML levels may flag higher PAD risk in older adults; hypothesis-generating and should not yet alter risk stratification.
Carboxymethyl-lysine is an advanced glycation end product that is detectable in the serum. Higher carboxymethyl-lysine levels have been associated with increased risk of coronary heart disease, stroke and cardiovascular mortality. We determined whether high carboxymethyl-lysine levels are also associated with the risk of peripheral artery disease in Cardiovascular Health Study participants who were all aged 65 years and older at baseline. Multivariate Cox proportional hazards models were used to determine the association of baseline carboxymethyl-lysine levels with incident peripheral artery disease in 3267 individuals followed for a median length of 10.0 years. A total of 157 cases of incident peripheral artery disease occurred during follow-up. No significant relationship between carboxymethyl-lysine and risk of peripheral artery disease was found (hazard ratio per standard deviation increment = 1.03; 95% confidence interval = 0.87, 1.23).
No takes yet. Share an insight, caveat, or question.
Garg et al. (2019) conducted a cohort in Peripheral artery disease (n=3,267). Carboxymethyl-lysine was evaluated on Incident peripheral artery disease (HR 1.03, 95% CI 0.87-1.23). Baseline carboxymethyl-lysine levels were not significantly associated with the risk of incident peripheral artery disease (HR per SD increment 1.03; 95% CI 0.87-1.23).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: